Analyst: AZ "worst performer" in pharma

So, Dresdner Kleinwort, tell us how you really feel about AstraZeneca. The investment bank, which just started covering AstraZeneca's stock, minced no words in its first report. The company's in "serious trouble," the analysts said, and quite possibly will be the worst performer in Big Pharma for the next eight years. At best, it'll manage a 1 percent growth in revenue, the analysts estimated; at worst, it'll drop 3 percent.

The basis for this bleak assessment? The company's three biggest sales-generators will get generic competition in the near future, and eight patents expire over the next eight years. Together that amounts to 60 percent of AZ's revenue. Even products ostensibly covered by patents through 2015, such as Nexium, Seroquel, and Crestor, face challenges that could expose them much, much sooner. The analysts weren't cheered by products coming up the pipeline, either.

Like all criticism, stock reports are subjective. Other analysts aren't as negative about AstraZeneca's prospects. And even the Kleinwort analyst said he was "mildly positive" about Crestor's approval for atherosclerosis treatment.

- read about Dresdner Kleinwort's rating at in-Pharma Technologist
- check out this assessment from New Ratings
- get more on Crestor from The Times

Related Articles:
AstraZeneca - Top 5 layoffs of 2007. Report
AstraZeneca lays out road map for recovery. Report
AstraZeneca announces restructuring and buyout. Report
AstraZeneca to continue ambitious deal-making. Report
AstraZeneca snares MedImmune in $15.6B buyout. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.